PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology
Federica Miglietta(University of Padua), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Pierfrancesco Franco(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Massimo Calabrese(University of Modena and Reggio Emilia), Michela Cinquini(Mario Negri Institute for Pharmacological Research), Filippo Montemurro(Roche (Switzerland)), Alberto Zambelli, Laura Biganzoli(Hospital of Prato), Laura Cortesi(Azienda Ospedaliero-Universitaria di Modena), Chiara Delle Piane(Ospedale Policlinico San Martino), Caterina Marchiò(Candiolo Cancer Institute), Lucio Fortunato(Azienda Ospedaliera San Giovanni Addolorata), Lucia Del Mastro(Ospedale Policlinico San Martino), Veronica Andrea Fittipaldo(Mario Negri Institute for Pharmacological Research), Maria Vittoria Dieci(Istituto Oncologico Veneto), Carmen Criscitiello(University of Milan), Bruno Meduri(Azienda Ospedaliero-Universitaria di Modena), Alessia Levaggi(Azienda Ospedaliera S.Maria)
Cited by 16
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830